blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2865392

EP2865392 - POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  10.01.2020
Database last updated on 20.09.2024
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL, IS		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
SK Bioscience Co., Ltd.
(Sampyeong-dong) 310, Pangyo-ro
Bundang-gu, Seongnam-si
Gyeonggi-do 13494 / KR
[2019/02]
Former [2018/28]For all designated states
SK Chemicals Co., Ltd.
Sampyeong-dong
310 Pangyo-ro
Bundang-gu
Seongnam-si, Gyeonggi-do 13494 / KR
Former [2018/27]For all designated states
SK Discovery Co., Ltd.
Sampyeong-dong
332, Pangyo-ro
Bundang-gu
Seongnam-si
Gyeonggi-do / KR
Former [2015/18]For all designated states
SK Chemicals Co., Ltd.
Sampyeong-dong
310 Pangyo-ro
Bundang-gu
Seongnam-si, Gyeonggi-do 463-400 / KR
Inventor(s)01 / SHIN, Jin-Hwan
1-502 Acazon Apt.
101-3(23/1)
Garak-dong
Songpa-gu
Seoul 138-160 / KR
02 / YANG, Ji-Hye
102-603 Humanville Apt.
456 Bukgajwa-dong
Seodaemun-gu
Seoul 120-813 / KR
03 / HAM, Dong-Soo
113-505 World Meridian Apt.
600 Uman-dong
Paldal-gu
Suwon-si Gyeonggi-do 442-754 / KR
04 / PARK, Mahn-Hoon
205-1703 Daeju Fiore Apt. B-danji
Gongse-dong
Giheung-gu
Yongin-si Gyeonggi-do 446-902 / KR
05 / KIM, Hun
108-1904 World Meridian Apt.
600 Uman-dong
Paldal-gu
Suwon-si Gyeonggi-do 442-754 / KR
06 / NOH, Myeong-Ju
3-108 Ildu Apt.
Seonghyeon-dong
Gwanak-gu
Seoul 151-763 / KR
07 / PARK, Su-Jin
294-2 Yatap-dong
Bundang-gu
Seongnam-si Gyeonggi-do 463-856 / KR
08 / YANG, Seon-Young
111-510 Sinbimaeul Apt.
Gwangyo-dong
Nam-gu
Incheon 402-709 / KR
 [2015/18]
Representative(s)Weickmann & Weickmann PartmbB
Postfach 860 820
81635 München / DE
[2016/46]
Former [2015/18]Weickmann & Weickmann
Postfach 860 820
81635 München / DE
Application number, filing date13806263.319.06.2013
[2016/46]
WO2013KR05392
Priority number, dateKR2012006589320.06.2012         Original published format: KR 20120065893
[2015/18]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013191459
Date:27.12.2013
Language:KO
[2013/52]
Type: A1 Application with search report 
No.:EP2865392
Date:29.04.2015
Language:EN
[2015/18]
Type: B1 Patent specification 
No.:EP2865392
Date:16.11.2016
Language:EN
[2016/46]
Type: B2 New European patent specification 
No.:EP2865392
Date:12.02.2020
Language:EN
[2020/07]
Search report(s)International search report - published on:KR27.12.2013
(Supplementary) European search report - dispatched on:EP22.12.2015
ClassificationIPC:A61K47/48, A61K31/70, A61K38/00, A61P31/00
[2015/18]
CPC:
A61K39/092 (EP,US); A61K39/09 (RU); A61K47/50 (KR,RU);
A61K39/39 (US); A61K31/70 (KR); A61K38/00 (KR);
A61K47/6415 (EP,US); A61K47/646 (EP,US); A61P11/00 (EP);
A61P31/00 (EP); A61P31/04 (EP); A61P37/02 (EP);
A61K2039/545 (US); A61K2039/55505 (US); A61K2039/6037 (EP,US);
A61K2039/70 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/18]
TitleGerman:POLYVALENTE PNEUMOKOKKEN-POLYSACCHARID-PROTEINKONJUGATZUSAMMENSETZUNG[2015/18]
English:POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION[2015/18]
French:COMPOSITION DE CONJUGUÉS POLYSACCHARIDE DE PNEUMOCOQUE-PROTÉINE POLYVALENTS[2015/18]
Entry into regional phase16.01.2015Translation filed 
16.01.2015National basic fee paid 
16.01.2015Search fee paid 
16.01.2015Designation fee(s) paid 
16.01.2015Examination fee paid 
Examination procedure16.01.2015Examination requested  [2015/18]
10.06.2016Communication of intention to grant the patent
07.10.2016Fee for grant paid
07.10.2016Fee for publishing/printing paid
07.10.2016Receipt of the translation of the claim(s)
26.04.2019Observations by third parties
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  10.06.2016
Opposition(s)Opponent(s)01  15.08.2017    ADMISSIBLE
GLAXO SMITHKLINE BIOLOGICALS S.A.
Rue de l'Institut 89
B-1330 Rixensart / BE
Opponent's representative
Baker, Suzanne J.
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
 [2017/38]
04.09.2017Invitation to proprietor to file observations on the notice of opposition
15.01.2018Reply of patent proprietor to notice(s) of opposition
05.03.2019Cancellation of oral proceeding that was planned for 12.03.2019
12.03.2019Date of oral proceedings
11.06.2019Despatch of interlocutory decision in opposition
21.06.2019Legal effect of interlocutory decision in opposition
10.12.2019Despatch of communication that the patent will be maintained as amended
23.12.2019Fee for printing new specification paid
Fees paidRenewal fee
30.06.2015Renewal fee patent year 03
31.05.2016Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.06.2013
AL16.11.2016
AT16.11.2016
BE16.11.2016
CY16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
MC16.11.2016
MK16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SI16.11.2016
SK16.11.2016
SM16.11.2016
TR16.11.2016
BG16.02.2017
NO16.02.2017
GR17.02.2017
IS16.03.2017
PT16.03.2017
IE19.06.2017
LU19.06.2017
MT19.06.2017
CH30.06.2017
LI30.06.2017
[2020/33]
Former [2020/15]HU19.06.2013
AT16.11.2016
BE16.11.2016
CY16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
MC16.11.2016
MK16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SI16.11.2016
SK16.11.2016
SM16.11.2016
TR16.11.2016
BG16.02.2017
NO16.02.2017
GR17.02.2017
PT16.03.2017
IE19.06.2017
LU19.06.2017
MT19.06.2017
CH30.06.2017
LI30.06.2017
Former [2019/51]HU19.06.2013
AT16.11.2016
BE16.11.2016
CY16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
MC16.11.2016
MK16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SI16.11.2016
SK16.11.2016
SM16.11.2016
BG16.02.2017
NO16.02.2017
GR17.02.2017
PT16.03.2017
IE19.06.2017
LU19.06.2017
MT19.06.2017
CH30.06.2017
LI30.06.2017
Former [2019/48]HU19.06.2013
AT16.11.2016
BE16.11.2016
CY16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
MC16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SI16.11.2016
SK16.11.2016
SM16.11.2016
BG16.02.2017
NO16.02.2017
GR17.02.2017
PT16.03.2017
IE19.06.2017
LU19.06.2017
MT19.06.2017
CH30.06.2017
LI30.06.2017
Former [2019/31]HU19.06.2013
AT16.11.2016
BE16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
MC16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SI16.11.2016
SK16.11.2016
SM16.11.2016
BG16.02.2017
NO16.02.2017
GR17.02.2017
PT16.03.2017
IE19.06.2017
LU19.06.2017
MT19.06.2017
CH30.06.2017
LI30.06.2017
Former [2018/43]AT16.11.2016
BE16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
MC16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SI16.11.2016
SK16.11.2016
SM16.11.2016
BG16.02.2017
NO16.02.2017
GR17.02.2017
PT16.03.2017
IE19.06.2017
LU19.06.2017
MT19.06.2017
CH30.06.2017
LI30.06.2017
Former [2018/21]AT16.11.2016
BE16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
MC16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SI16.11.2016
SK16.11.2016
SM16.11.2016
BG16.02.2017
NO16.02.2017
GR17.02.2017
PT16.03.2017
LU19.06.2017
CH30.06.2017
LI30.06.2017
Former [2018/11]AT16.11.2016
BE16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
MC16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SI16.11.2016
SK16.11.2016
SM16.11.2016
BG16.02.2017
NO16.02.2017
GR17.02.2017
PT16.03.2017
Former [2017/52]AT16.11.2016
BE16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SI16.11.2016
SK16.11.2016
SM16.11.2016
BG16.02.2017
NO16.02.2017
GR17.02.2017
PT16.03.2017
Former [2017/38]AT16.11.2016
BE16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SK16.11.2016
SM16.11.2016
BG16.02.2017
NO16.02.2017
GR17.02.2017
PT16.03.2017
Former [2017/37]AT16.11.2016
BE16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SK16.11.2016
SM16.11.2016
NO16.02.2017
GR17.02.2017
PT16.03.2017
Former [2017/36]AT16.11.2016
BE16.11.2016
CZ16.11.2016
DK16.11.2016
EE16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
PL16.11.2016
RO16.11.2016
RS16.11.2016
SE16.11.2016
SK16.11.2016
NO16.02.2017
GR17.02.2017
PT16.03.2017
Former [2017/34]AT16.11.2016
CZ16.11.2016
DK16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
PL16.11.2016
RS16.11.2016
SE16.11.2016
NO16.02.2017
GR17.02.2017
PT16.03.2017
Former [2017/33]AT16.11.2016
DK16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
PL16.11.2016
RS16.11.2016
SE16.11.2016
NO16.02.2017
GR17.02.2017
PT16.03.2017
Former [2017/26]AT16.11.2016
FI16.11.2016
HR16.11.2016
LT16.11.2016
LV16.11.2016
PL16.11.2016
RS16.11.2016
SE16.11.2016
NO16.02.2017
GR17.02.2017
PT16.03.2017
Former [2017/12]LV16.11.2016
Documents cited:Search[A]WO0168128  (AVENTIS PASTEUR [FR], et al) [A] 1,2,7,8* pages 7-9 *;
 [A]WO2009000825  (GLAXOSMITHKLINE BIOLOG SA [BE], et al) [A] 1-8 * page 9, lines 21-23; claims 1-21 *;
 [A]CN101590224  (GUANGZHOU JINGDA MEDICAL SCIEN [CN]) [A] 1-8 * pages 1-2 *;
 [A]WO2012078482  (MERCK SHARP & DOHME [US], et al) [A] 1-8 * page 3, lines 8-35; claims 14-17 * * page 11, lines 10-30 * * pages 10-13 *;
 [A]  - JULIE M SKINNER ET AL, "Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model", VACCINE, ELSEVIER LTD, GB, vol. 29, no. 48, doi:10.1016/J.VACCINE.2011.09.078, ISSN 0264-410X, (20110920), pages 8870 - 8876, (20110922), XP028326015 [A] 1-8

DOI:   http://dx.doi.org/10.1016/j.vaccine.2011.09.078
International search[A]US5153312  (PORRO MASSIMO [IT]);
 [A]US2003147922  (CAPIAU CARINE [BE], et al);
 [A]US2004202668  (BOUTRIAU DOMINIQUE [BE], et al);
 [A]CN101590224  (GUANGZHOU JINGDA MEDICAL SCIEN [CN]);
 [A]US2010316666  (HAUSDORFF WILLIAM P [US], et al);
 [A]WO2011151760  (WYETH LLC [US], et al)
by applicantUS4673574
 US4902506
 US4912094
 WO9014837
 US5057540
 WO9219265
 WO9313302
 US5614382
 US5847112
 WO0018434
 US6113918
 US6207646
 WO02053761
 WO02083855
 WO02098368
 WO02098369
 WO2004083251
    - HARBOE ZB; BENFIELD TL; VALENTINER-BRANTH P ET AL., "Temporal Trends in Invasive Pneumococcal Disease and Pneumococcal Serotypes over 7 Decades", CLIN INFECT DIS, (2010), vol. 50, pages 329 - 37
    - SAHA SK; AL EMRAN HM; HOSSAIN B; DARMSTADT GL; SAHA S, "Streptococcus pneumoniae Serotype-2 Childhood Meningitis in Bangladesh: A Newly Recognized Pneumococcal Infection Threat", PLOS ONE, (2012), vol. 7, no. 3, page E32134
OppositionUS5153312
 WO0168128
 US2003147922
 US2004202668
 US2006228380
 WO2006110381
 WO2009000825
 CN101590224
 WO2010125480
 US2010316666
 WO2011100151
 WO2011151760
 WO2012078482
    - JULIE M SKINNER et al., "Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model", VACCINE, (20110920), vol. 29, no. 48, pages 8870 - 8876, XP028326015

DOI:   http://dx.doi.org/10.1016/j.vaccine.2011.09.078
    - CHULMIN PARK et al., "Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model", HUMAN VACCINES & IMMUNOTHERAPEUTICS, (20161214), vol. 13, no. 5, pages 1169 - 1176, XP055410253

DOI:   http://dx.doi.org/10.1080/21645515.2016.1261772
    - Wyeth Pharmaceuticals Inc., "PREVNAR 13", Highlights of Prescribing Information, (20100400), pages 1 - 24, XP055410260
    - Duff Wilson, "Vaccine Approved for Child Infections", THE NEW YORK TIMES, (20100224), URL: http://www.nytimes.com/2010/02/25/business/25vaccine.html, XP055410266
    - SAMIR K SAHA et al., "Streptococcus pneumoniae Serotype-2 Childhood Meningitis in Bangladesh: A Newly Recognized Pneumococcal Infection Threat", PLOS ONE, (20120330), vol. 7, no. 3, pages e32134-1 - e32134-7, XP055410278
    - FABIO BAGNOLI et al., "A Second Pilus Type in Streptococcus pneumoniae Is Prevalent in Emerging Serotypes and Mediates Adhesion to Host Cells", JOURNAL OF BACTERIOLOGY, (20080521), vol. 190, no. 15, pages 5480 - 5492, XP055410289
    - ORLANDO CESAR MANTESE et al., "Prevalence of serotypes and antimicrobial resistance of invasive strains of pneumococcus in children: analysis of 9 years", Journal de PEDIATRIA, (20090000), vol. 85, no. 6, pages 495 - 502, XP055410299
    - DANIEL M WEINBERGER et al., "Association of Serotype with Risk of Death Due to Pneumococcal Pneumonia: A Meta-Analysis", CLINICAL INFECTIOUS DISEASES, (20100915), vol. 51, no. 6, pages 692 - 699, XP055410304
    - Pfizer Inc., "Pfizer Receives FDA Approval for Prevnar 13™ for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children", Pfizer Press Release, (20100224), URL: http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW_I%20D=%2017021#.WYHK0flrtgU, XP055411054
    - KRISTINA A BRYANT et al., "Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine", PEDIATRICS, (20100500), vol. 125, no. 5, pages 866 - 875, XP002702850

DOI:   http://dx.doi.org/10.1542/peds.2009-1405
    - ALLANA J SUCHER et al., "Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine", The ANNALS OF PHARMACOTHERAPY, (20111200), vol. 45, no. 12, pages 1516 - 1524, XP055411056
    - Selva L; et al.,, "Serotype 3 is a common serotype causing invasive pneumococcal disease in children less than 5 years old, as identified by real-time D26 PCR", European Journal of Clinical Microbiology & Infectious Diseases, (20120700), vol. 31, no. 7, pages 1487 - 1495, XP035064020

DOI:   http://dx.doi.org/10.1007/s10096-011-1468-7
    - Wyeth Pharmaceuticals Inc., "PREVNAR 13", Highlights of Prescribing Information, (201004), pages 1 - 24
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.